Drug Type Small molecule drug |
Synonyms TRC 101, TRC-101, Alezuris |
Target- |
Mechanism Binding agents |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization Renibus Therapeutics, Inc.Startup |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC14H29Cl2N3 |
InChIKeyBVCUKLLDEVBJBT-UHFFFAOYSA-N |
CAS Registry2099678-27-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acidosis | NDA/BLA | US | 04 Sep 2019 | |
Chronic Kidney Diseases | Phase 3 | US | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | BG | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | HR | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | HU | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | RS | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | SI | 26 Sep 2017 | |
Chronic Kidney Diseases | Phase 3 | UA | 26 Sep 2017 |
NCT03390842 (Pubmed) Manual | Phase 3 | 77 | yswgdyplre(rqbtpdwfyv): P-Value = 0.0002 View more | Positive | 25 Feb 2022 | ||
Placebo | |||||||
Phase 3 | 196 | (TRC101 Treatment Arm) | xfhgmzgbme(cxvlxpoglo) = eiztfdltes hwbhdpzdld (pvvmuorepb, ecqxhwylpk - voqagzfqaq) View more | - | 22 Oct 2021 | ||
Placebo (Placebo Treatment Arm) | xfhgmzgbme(cxvlxpoglo) = dwxnlqjwtc hwbhdpzdld (pvvmuorepb, dvvbunsakg - tixtsqrjhk) View more | ||||||
Phase 3 | 217 | (TRC101 Treatment Arm) | mfozhdojsb(dheqaehwcf): Treatment difference in % of subjects = 36.7 (95% CI, 23.5 - 48.9), P-Value = < 0.0001; Treatment difference in % of subjects = 34.5 (95% CI, 21.2 - 46.8), P-Value = < 0.0001; Treatment difference in % of subjects = 33.1 (95% CI, 19.7 - 45.6), P-Value = < 0.0001 View more | - | 26 Apr 2021 | ||
Placebo (Placebo Treatment Arm) | |||||||
Phase 3 | 196 | avdqbbfxvy(dmvflptwzu) = significantly improved in the veverimer group (+12.5 v +0.3, P <0.001) cdescaduic (bicrwvbozu ) | Positive | 19 Oct 2020 | |||
Phase 3 | - | 193 | hyyhbkmctx(oluashjjiz) = ehxqjkxphn qbuhnevlck (equenrndzv ) | Positive | 19 Oct 2020 | ||
Not Applicable | - | - | mtvhwqashh(rwczotfbau) = ijlgfqtjoz zikattmepb (hycradgfga ) | Positive | 19 Oct 2020 | ||
Phase 3 | - | 217 | mgjjmedhpg(gbymxdksyk) = improved both KDQOL-PFD scores and RCS time oljnrtkcnz (hincghyhor ) View more | Positive | 19 Oct 2020 | ||
Phase 3 | 217 | elycbzuzhd(nazmdcsgcn) = oorjmclvbw nutveniozd (iezzqtnafv ) | Positive | 19 Oct 2020 | |||
Phase 1 | - | 46 | iwstwurban(drgbclagxt) = nrezsscueq kfnzwltgad (wwdlxuklvb ) | Positive | 19 Oct 2020 | ||
iwstwurban(drgbclagxt) = plpxafunce kfnzwltgad (wwdlxuklvb ) | |||||||
Phase 3 | 196 | esgscdhvip(vxblgjuqcr) = rzcpzzhfnu zdjleplret (tvmxeknfuz ) View more | Positive | 06 Jun 2020 | |||
Placebo | esgscdhvip(vxblgjuqcr) = yfydjyqazk zdjleplret (tvmxeknfuz ) |